無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

経肺ドラッグデリバリーシステム:各種技術と世界の市場

Pulmonary Drug Delivery Systems: Technologies and Global Markets

発行 BCC Research 商品コード 224407
出版日 ページ情報 英文 121 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.03円で換算しております。
Back to Top
経肺ドラッグデリバリーシステム:各種技術と世界の市場 Pulmonary Drug Delivery Systems: Technologies and Global Markets
出版日: 2018年04月24日 ページ情報: 英文 121 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の経肺ドラッグデリバリーシステムの市場は予測期間中4.3%のCAGR (年間複合成長率) で推移し、2017年の381億ドルから、2022年には470億ドルの規模に成長すると予測されています。

当レポートでは、経肺ドラッグデリバリーシステムの技術および市場を調査し、市場の定義と概要、肺疾患と治療薬、市場成長への各種影響因子および市場機会の分析、関連法規制、システム区分・疾患区分・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場力学・技術背景

  • 市場の定義・概要
    • 作用機序
    • メリット
    • 制約・課題
  • 肺疾患と治療薬
  • 市場成長推進因子・動向
  • 市場成長抑制因子
  • 市場機会
  • 法規制環境

第4章 市場分析・予測:システム区分別

  • 吸入法:概要
  • 主な呼吸器製品
  • ドライパウダー吸入器 (DPI)
    • 概要
    • 上市済み製品
    • 市場規模・予測
  • 定量噴霧式吸入器 (MDI)
    • 概要
    • 上市済み製品
    • 市場規模・予測
  • ネブライザー
    • 概要
    • 上市済み製品の概要:製造業別
    • 市場規模・予測

第5章 利用されている経肺ドラッグデリバリーシステムシステム

  • 吸入投与剤
    • ステロイド
    • 気管支拡張剤

第6章 市場分析・予測:疾患区分別

  • イントロダクション
  • 喘息
    • 喘息発作
    • 喘息と肥満
    • 死亡率
    • 疾患の分類
    • 診断
    • 治療・治療薬
    • 市場規模・予測
  • 慢性閉塞性肺疾患 (COPD)
    • 診断
    • 治療・治療薬
    • 市場規模・予測
  • その他
    • 市場規模・予測

第7章 市場分析・予測:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スぺイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • その他
  • 中東・アフリカ
  • 南米

第8章 競合環境・主な展開

  • 主要企業・市場構造の分析
  • 特許分析
    • 主要特許
    • パイプラインの分析
  • 主な展開
    • M&A
    • 革新的製品の開発・新製品の投入
    • 合意・提携・協力

第9章 企業プロファイル

付録

BCC Researchについて

図表

List of Tables

  • Summary Table A Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2022 ($ Millions)
  • Summary Table B Global Market for Pulmonary Drug Delivery Systems, by Region Through 2022 ($ Millions)
  • Table 1 Global Asthma and COPD Snapshot, 1990-2015
  • Table 2 Key Products Going off-Patent, 2016-2021
  • Table 3 Inhaler Device Characteristics Snapshot
  • Table 4 Global Market for Pulmonary Drug, by Delivery System, Through 2022 ($ Millions)
  • Table 5 Global Respiratory Product Sales, 2014-2016 ($ Millions)
  • Table 6 Capsule Based Inhaler Devices
  • Table 7 Blister Based Inhaler Devices
  • Table 8 Reservoir/Cartridge Based Inhaler Devices
  • Table 9 Global Dry Powder Inhaler Market, by Region, Through 2022 ($ Millions)
  • Table 10 MDIs, HFA Propellant
  • Table 11 MDIs, Anti-Inflammatory Medicine
  • Table 12 MDIs, Combination Medicine
  • Table 13 Commonly Used MDIs
  • Table 14 Global MDI Market, by Region, Through 2022 ($ Millions)
  • Table 15 Comparison of Nebulizers
  • Table 16 Marketed Nebulizers by Manufacturer
  • Table 17 Global Nebulizer Market, by Region, Through 2022 ($ Millions)
  • Table 18 Inhaled Steroids
  • Table 19 Inhaled Corticosteroids
  • Table 20 Inhaled Corticosteroids, Combination Inhalers
  • Table 21 Short-Acting Inhaled Beta-Agonist Bronchodilators
  • Table 22 Short-Acting Inhaled Muscarinic Antagonist Combination Bronchodilators
  • Table 23 Long-Acting Inhaled LABAs (Long-Acting Beta2 Agonists)
  • Table 24 Long-Acting Inhaled LAMAs (Long-Acting Muscarinic Antagonists)
  • Table 25 LABA and LAMA Combinations
  • Table 26 Top Asthma/COPD Product Sales, 2015-2017 ($ Millions)
  • Table 27 U.S. Asthma Mortality, 2015
  • Table 28 U.S. Asthma Prevalence, 2015
  • Table 29 Global Asthma Market, by Region Through 2022 ($ Millions)
  • Table 30 Global COPD Market, by Region, Through 2022 ($ Millions)
  • Table 31 Global Market for Other Pulmonary Diseases, by Region, Through 2022 ($ Millions)
  • Table 32 Canadian Disease Prevalence, Asthma and COPD, 2012-2014 (Number of Persons)
  • Table 33 European Self-Reported Asthma, 2014 (% of Population)
  • Table 34 European Self-Reported COPD, 2014 (% of Population)
  • Table 35 Leading Causes of Death in Australia, 2011-2016
  • Table 36 Patent Review, Inhaler, 2013-2018
  • Table 37 Sunovion Pharmaceuticals, Inc., SUN-101/ eFlow (Glycopyrrolate), 2017
  • Table 38 AstraZeneca plc, (Pearl Therapeutics), Pulmonary Products Pipeline
  • Table 39 Teva Pharmaceuticals Industries Ltd., Pulmonary Products Pipeline
  • Table 40 Vectura Group plc, Pulmonary Products Pipeline
  • Table 41 GlaxoSmithKline plc, Pulmonary Products Pipeline
  • Table 42 3M Pharmaceuticals, Inc., Marketed Products, 2016
  • Table 43 3M Pharmaceuticals, Inc., Net Revenue, 2015-2017 ($ Millions)
  • Table 44 AstraZeneca plc, Marketed Products, 2016
  • Table 45 AstraZeneca plc., Key Developments, 2016
  • Table 46 AstraZeneca plc, Net Revenue, 2014-2016 ($ Millions)
  • Table 47 Boehringer Ingelheim GmbH, Marketed Product, 2016
  • Table 48 Boehringer Ingelheim GmbH, Net Revenue, 2014-2016 ($ Millions)
  • Table 49 Cipla, Inc., Marketed Products, 2016
  • Table 50 Cipla, Inc., Net Revenue, 2015-2017 ($ Millions)
  • Table 51 Dr. Reddy's Laboratories Ltd., Marketed Products, 2016
  • Table 52 Dr. Reddy's Laboratories Ltd., Net Revenue, 2015-2017 ($ Millions)
  • Table 53 GlaxoSmithKline plc, Marketed Products, 2016
  • Table 54 GlaxoSmithKline plc, Net Revenue, 2014-2016 ($ Millions)
  • Table 55 Koninklijke Philips N.V., Marketed Products, 2016
  • Table 56 Lupin Limited, Key Developments
  • Table 57 Lupin Limited, Net Revenue, 2015-2017 ($ Millions)
  • Table 58 Mylan N.V., Marketed Products, 2016
  • Table 59 Mylan N.V., Key Developments, 2016
  • Table 60 Mylan N.V., Net Revenue, 2015-2017 ($ Millions)
  • Table 61 Novartis AG, Marketed Products, 2016
  • Table 62 Novartis AG, Key Developments, 2016
  • Table 63 Novartis AG, Net Revenue, 2014-2016 ($ Millions)
  • Table 64 Omron Corp., Marketed Products, 2016
  • Table 65 Omron Corp., Net Revenue, 2014-2016 ($ Millions)
  • Table 66 Pfizer, Inc., Marketed Products, 2016
  • Table 67 Pfizer, Inc., Net Revenue, 2014-2016 ($ Millions)
  • Table 68 Teva Pharmaceutical Industries Ltd., Marketed Products, 2016
  • Table 69 Teva Pharmaceutical Industries Ltd., Net Revenue, 2014-2016 ($ Millions)
  • Table 70 Vectura Group plc, Marketed Products, 2016
  • Table 71 Vectura Group plc, Net Revenue, 2015-2017 ($ Millions)
  • Table 72 Abbreviations Used in Pulmonary Drug Delivery Systems

List of Figures

  • Summary Figure A Global Market for Pulmonary Drug Delivery Systems, by Type, 2016-2022 ($ Millions)
  • Summary Figure B Global Market for Pulmonary Drug Delivery Systems, by Region, 2016-2022 ($ Millions)
  • Figure 1 Estimation of Daily Smoking Patterns, by Region, 2015 (Millions)
  • Figure 2 Global Market for Pulmonary Drug, by Delivery System, 2016-2022 ($ Millions)
  • Figure 3 Global Dry Powder Inhaler Market, by Region, 2016-2022 ($ Millions)
  • Figure 4 Global MDI Market, by Region, 2016-2022 ($ Millions)
  • Figure 5 Global Nebulizer Market, by Region, 2016-2022 ($ Millions)
  • Figure 6 Non-communicable Disease Mortality Share, by Cause of Death, 2015 (%)
  • Figure 7 Global Asthma Market, 2016-2022 ($ Millions)
  • Figure 8 Global Asthma Market, by Region, 2016-2022 ($ Millions)
  • Figure 9 Top 10 Leading Causes of Death in the World, 2015 (Millions)
  • Figure 10 Global COPD Market, 2016-2022 ($ Millions)
  • Figure 11 Global COPD Market, by Region, 2016-2022 ($ Millions)
  • Figure 12 Global Market for Other Pulmonary Disease, 2016-2022 ($ Millions)
  • Figure 13 Global Market for Other Pulmonary Disease, by Region, 2016-2022 ($ Millions)
  • Figure 14 North American Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 15 Impact of Asthma in North America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 16 Impact of COPD in North America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 17 Mexican Population Health Issues, Proportional Mortality, 2014 (%)
  • Figure 18 Impact of Asthma in Europe, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 19 Impact of COPD in Europe, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 20 European Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 21 United Kingdom Mortality Rates in Males, 2015 (%)
  • Figure 22 United Kingdom Mortality Rate in Females, 2015 (%)
  • Figure 23 Leading Causes of Death in Italy in Percent Change, 2005-2016
  • Figure 24 Spain Mortality Rate in Women, 2014 (%)
  • Figure 25 Spain Mortality Rate in Men, 2014 (%)
  • Figure 26 Leading Causes of Death in Europe, 2015
  • Figure 27 Asia Pacific Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 28 Impact of Asthma in Asia, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 29 Impact of COPD in Asia, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 30 Impact of Asthma in Middle East and Africa, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 31 Impact of COPD in Middle East and Africa, Annual Mortality Rate, 2016 (Per 100,000 People) 81
  • Figure 32 Middle East and African Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 33 Impact of Asthma in South America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 34 Impact of COPD in South America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 35 Impact of COPD in South America, Annual Mortality Rate, 2016 (Per 100,000 People)
  • Figure 36 South American Pulmonary Drug Delivery Systems Market, 2016-2022 ($ Millions)
  • Figure 37 3M Pharmaceuticals, Inc., Revenue Share by Region, 2016 (%)
  • Figure 38 3M Pharmaceuticals, Inc., Revenue Share by Business Segment, 2016 (%)
  • Figure 39 AstraZeneca plc, Revenue Share, by Region, 2016 (%)
  • Figure 40 AstraZeneca plc, Revenue Share, by Business Segment, 2016 (%)
  • Figure 41 Boehringer Ingelheim GmbH, Research and Development Expenditure, 2014-2016 ($ Millions)
  • Figure 42 Boehringer Ingelheim GmbH, Revenue Share by Region, 2016 (%)
  • Figure 43 Boehringer Ingelheim GmbH, Revenue Share, by Business Segment, 2016 (%)
  • Figure 44 Cipla, Inc. Research and Development Expenditure, 2014-2017 (%)
  • Figure 45 Cipla, Inc., Revenue Share, by Region, 2017 (%)
  • Figure 46 Cipla, Inc., Revenue Share, by Business Segment, 2017 (%)
  • Figure 47 Dr. Reddy's Laboratories Ltd., Revenue Share, by Region, 2017 (%)
  • Figure 48 Dr. Reddy's Laboratories Ltd., Revenue Share, by Business Segment, 2017 (%)
  • Figure 49 GlaxoSmithKline plc, Pharmaceuticals Revenue Share, by Therapy Areas, 2016 (%) 120
  • Figure 50 GlaxoSmithKline plc, Revenue Share, by Region, 2016 (%)
  • Figure 51 Mylan N.V., Revenue Share by Therapy Areas, 2016 (%)
  • Figure 52 Mylan N.V., Revenue Share, by Region, 2016 (%)
  • Figure 53 Novartis AG, Revenue Share, by Region, 2016 (%)
  • Figure 54 Novartis AG, Revenue Share, by Business Segment, 2016 (%)
  • Figure 55 Omron Corp., Revenue Share, by Healthcare Business Segment (HCB), 2017 (%)
  • Figure 56 Omron Corp., Revenue Share, by Region, 2017 (%)
  • Figure 57 Pfizer, Inc., Revenue Share, by Region, 2016 (%)
  • Figure 58 Pfizer, Inc., Revenue Share, by Business Segment, 2016 (%)
  • Figure 59 Teva Pharmaceutical Industries Ltd., Revenue Share, by Region, 2017 (%)
  • Figure 60 Teva Pharmaceutical Industries Ltd., Revenue Share, by Business Segment, 2016 (%) .
  • Figure 61 Vectura Group plc, Research and Development Expenditure, 2014-2016 ($ Millions)
  • Figure 62 Vectura Group plc, Revenue Share, by Region, 2017 (%)
目次
Product Code: HLC094C

The global pulmonary drug delivery systems market totaled $38.1 billion in 2017 and is estimated to reach $47.0 billion by 2022, growing at a compound annual growth rate (CAGR) of 4.3% for the period of 2017-2022.

Report Includes

  • 74 tables
  • A detailed overview and analysis of the global markets for pulmonary drug delivery systems
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
  • A look at the regulatory environment, which has been a driving force in the healthcare industry
  • Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
  • Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd

Report Scope

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, research and development pipeline, and blockbuster drugs.

In the report the regulatory scenario of pulmonary drug delivery systems is discussed for device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are analyzed in the Pipeline Analysis section.

A discussion of the major players is included in the Competitive Landscape section. The Competitive Landscape section provides trends in product launch, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the pulmonary drug delivery systems market are included with an overview, key product offerings, financials, strategies, strength, weakness, opportunities and threats (SWOT) and developments. The report will be useful for analysis of the leading products and will enable readers to recognize growing brands, key device types and leading manufacturing companies with significant market share.

Analyst Credentials

Led by Research Head Karthik Arun, the BCC Research staff is composed of expert analysts skilled in conducting primary research, secondary research and data analysis and who have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in microbiology, electrical engineering, business administration, surgery and other subject areas.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Dynamics and Technology Background

  • Market Definition and Overview
    • Mechanism of Action
    • Advantages
    • Limitations/Challenges
  • Pulmonary Conditions and Therapies
    • Introduction to the Respiratory System
  • Market Driving Factors and Trends
    • Improved Patient Compliance and Ease of Use Leading to Adoption of Inhalation Products
    • Cost Pressure on Countries Imposing Adoption of Cost-Effective Devices
    • Rising Incidence of Asthma and COPD in Developing and Developed Regions
  • Market Restraints
    • Competition from Generics on the Rise Due to Patent Expiry of Blockbuster Products
  • Market Opportunities
    • Introduction of Smart Nebulizers
  • Regulation and Legislation
    • United States

Chapter 4: Market Breakdown by Pulmonary Drug Delivery Systems

  • Overview of Inhalation Techniques
  • Leading Respiratory Products
  • Dry Powder Inhalers (DPIs)
    • Overview
    • Marketed Products
    • Market Size and Forecast
  • Metered Dose Inhalers (MDI's)
    • Overview
    • Marketed Products
    • Market Size and Forecast
  • Nebulizers
    • Overview
    • Marketed Products Overview by Manufacturer
    • Market Size and Forecast

Chapter 5: Pulmonary Drug Delivery Systems in Use

  • Therapeutic Agents Administered via Inhalation
    • Steroids
    • Bronchodilators

Chapter 6: Market Breakdown by Disease Area

  • Introduction
  • Asthma
    • Asthma Attack
    • Asthma and Obesity
    • Mortality
    • Disease Classification
    • Diagnosis
    • Treatment and Therapies
    • Market Size and Forecasts
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Diagnosis
    • Treatment and Therapies
    • Market Size and Forecast
  • Other Diseases
    • Market Size and Forecast

Chapter 7: Market Breakdown by Region

  • North America
    • U.S.A.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa
  • South America

Chapter 8: Competitive Landscape and Key Developments

  • Leading Players and Market Structure Analysis
  • Patent Analysis
    • List of Key Patents
    • Pipeline Analysis
  • Key Developments
    • Mergers and Acquisitions
    • Development of Innovative Products/Novel Product Launches
    • Agreements, Collaborations and Partnerships

Chapter 9: Company Profiles

Appendix

  • Acronyms

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research
Back to Top